EIPM Clinical Director recognized as one of the 2025 Best Female Scientists in the World!
February 9, 2026
February 2026 EIPM Director's Memo
February 9, 2026
Dear Friends & Members of the Englander Institute,
New Laboratory to Advance Personalized, Cell-Based Cancer Therapies
February 5, 2026
Dr. George Coukos, an internationally renowned expert on cancer immunology, is on a mission to rapidly translate tumor biology research into personalized, cell-based therapies for patients with some of the hardest-to-treat cancers. A new laboratory, part of an innovative collaboration between Weill Cornell Medicine and the Ludwig Institute for Cancer Research, seeks to do just that.
Renowned Cell Therapy Expert Joins the EIPM!
February 4, 2026
Dr. George Coukos, a physician-scientist and international authority on tumor immunology and cellular immunotherapy, is joining Weill Cornell Medicine on Feb. 1 to lead the new Ludwig Laboratory for Cell Therapy. He previously was founding director of the Ludwig Lausanne Branch in Switzerland.
December 2025 EIPM Town Hall Highlights
January 19, 2026
“Vision, Growth, and Priorities.”
Highlights from the December 18th Town Hall by EIPM Director Olivier Elemento, Ph.D.
The Englander Institute for Precision Medicine gathered faculty, staff, and trainees for our annual Town Hall meeting on December 18th led by Director Olivier Elemento, Ph.D., who used the occasion to focus on the EIPM’s future direction, ongoing initiatives, and strategic priorities, highlighting both significant accomplishments and the challenges ahead.
Mission Remains Steady Amid Change
Whole-Genome Sequencing May Optimize PARP Inhibitor Use
January 12, 2026
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest further development of this approach is merited.
EIPM's Fourth Quarter External Newsletter
January 6, 2026
Dear Friends & Members of the Englander Institute,
Welcome to fourth quarterly external newsletter of 2025!
January 2026 EIPM Director's Memo
January 5, 2026
January 2026 EIPM Director's Memo
Dear Friends & Members of the Englander Institute,
December 2025 EIPM Director's Memo
December 10, 2025
Dear Friends & Members of the Englander Institute,
Bridging the gap between lab research and clinical care
December 3, 2025
Q: Ben, you're the EIPM's Director of Ex Vivo Models. Can you explain what you do?
A: Sure. The EIPM Ex Vivo Models Group receives tissues from patients with cancer, usually advanced cases. Our team builds organoid models of these tumors to test different therapeutics, aiming to find new treatments and improve patient care. The overarching goal is to translate research findings into the clinic to benefit patients.